Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771105 | 0.90 | GSK3B (0.39) | POLQCYP3A4SMN1; SMN2S1PR1NPC1 | |
| SCHEMBL5773874 | 0.84 | MAPT (0.42) | CYP3A4MAPTSMN1; SMN2TSPO | |
| SCHEMBL5774478 | 0.84 | HIF1A (0.42) | CYP3A4MAPTSMN1; SMN2TSPOS1PR1 | |
| SCHEMBL5776431 | 0.83 | MET (0.37) | MAPTTSPONPC1HDAC1HDAC2 | |
| SCHEMBL5771067 | 0.82 | HDAC8 (0.35) | HDAC8GSK3B | |
| SCHEMBL5772985 | 0.79 | GSK3B (0.41) | SMN1; SMN2S1PR1HDAC1HDAC2HDAC8 | |
| SCHEMBL5775722 | 0.79 | GSK3B (0.41) | SMN1; SMN2S1PR1HDAC1HDAC2HDAC8 | |
| SCHEMBL5907124 | 0.77 | FAAH (0.36) | POLQHDAC1HDAC2HDAC8TRPV1 | |
| SCHEMBL5776662 | 0.77 | TRPV1 (0.37) | CYP3A4SMN1; SMN2NPC1HDAC1HDAC2 | |
| SCHEMBL5774573 | 0.76 | LMNA (0.40) | NPC1HDAC1HDAC2HDAC8GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | POLQ 4531/4885CYP3A4 39/4885MAPT 4701/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | POLQ 4458/4885CYP3A4 76/4885MAPT 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.